- Home
- REGN vs NXPI Comparison
REGN vs NXPI Comparison
Compare REGN & NXPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REGN | NXPI |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8B | 57.0B |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | REGN | NXPI |
|---|---|---|
| Price | $827.26 | $227.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 21 |
| Target Price | ★ $830.16 | $285.76 |
| AVG Volume (30 Days) | 565.1K | ★ 2.7M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | 0.55% | ★ 1.40% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 18.95 | 4.43 |
| Revenue | $5,872,227,000.00 | ★ $12,269,000,000.00 |
| Revenue This Year | $12.45 | $12.56 |
| Revenue Next Year | $10.13 | $10.17 |
| P/E Ratio | ★ $44.35 | $51.01 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $541.00 | $183.00 |
| 52 Week High | $859.34 | $339.95 |
Technical Indicators
Market Signals| Indicator | REGN | NXPI |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 41.04 |
| Support Level | $732.04 | $218.78 |
| Resistance Level | $847.00 | $243.94 |
| Average True Range (ATR) | 19.34 | 5.39 |
| MACD | -3.02 | 1.81 |
| Stochastic Oscillator | 76.33 | 41.62 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About NXPI NXP Semiconductors N.V.
NXP Semiconductors is a leading supplier of high-performance mixed-signal products. The firm acquired Freescale Semiconductor in 2015 and now has significant market share in the automotive market, where it supplies microcontrollers and analog chips into automotive clusters, powertrains, infotainment systems, and radars. NXP Semiconductors also serves industrial and Internet of Things, mobile, and communications infrastructure.